Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Legat

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
British Journal of Pharmacology|June 1, 1997
Effects of the non-peptide B2 antagonist FR173657 on kinin-induced smooth muscle contraction and relaxation, vasoconstriction and prostaglandin releaseT Griesbacher, W Sametz, F J Legat, et al.
The British Journal of Dermatology|December 11, 2008
Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanerceptP Wolf, A Hofer, F J Legat, et al.
The British Journal of Dermatology|March 25, 2011
Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D₃ analogue in polymorphic light eruptionA Gruber-Wackernagel, I Bambach, F J Legat, et al.
Journal of Chemotherapy (Florence, Italy)|December 6, 2005
Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycinD Stengel, E Görzer, M Schintler, et al.
The British Journal of Dermatology|September 14, 2011
Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trialP Wolf, W Weger, F J Legat, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 29, 2022
Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbancesS Ständer, G Yosipovitch, J-P Lacour, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndromeF J Legat, A Maier, P Dittrich, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infectionF J Legat, R Krause, P Zenahlik, et al.
The British Journal of Dermatology|May 14, 2011
Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registryM Inzinger, B Heschl, W Weger, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 15, 2021
Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phaseE Weisshaar, J C Szepietowski, J D Bernhard, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
British Journal of Pharmacology|June 1, 1997
Effects of the non-peptide B2 antagonist FR173657 on kinin-induced smooth muscle contraction and relaxation, vasoconstriction and prostaglandin releaseT Griesbacher, W Sametz, F J Legat, et al.
The British Journal of Dermatology|December 11, 2008
Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanerceptP Wolf, A Hofer, F J Legat, et al.
The British Journal of Dermatology|March 25, 2011
Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D₃ analogue in polymorphic light eruptionA Gruber-Wackernagel, I Bambach, F J Legat, et al.
Journal of Chemotherapy (Florence, Italy)|December 6, 2005
Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycinD Stengel, E Görzer, M Schintler, et al.
The British Journal of Dermatology|September 14, 2011
Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trialP Wolf, W Weger, F J Legat, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 29, 2022
Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbancesS Ständer, G Yosipovitch, J-P Lacour, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndromeF J Legat, A Maier, P Dittrich, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infectionF J Legat, R Krause, P Zenahlik, et al.
The British Journal of Dermatology|May 14, 2011
Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registryM Inzinger, B Heschl, W Weger, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 15, 2021
Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phaseE Weisshaar, J C Szepietowski, J D Bernhard, et al.
Pageof 4